Bruce Carter, PhD


Dr. Bruce Carter is a c-level executive and board director with experience in American, European and Asian
companies in both the public and private sectors. Dr. Carter serves as a Director on the Boards of: Dr. Reddy’s
Laboratories Limited and Accelerator portfolio companies: ApoGen Biotechnologies, Lodo Therapeutics and
Rodeo Therapeutics. Dr. Carter has also served as Chairman of the Board of TB Alliance for over 11 years. Dr.
Carter is an affiliate Professor in the Department of Biotechnology at the University of Washington, Seattle
Washington, a position he has held since 1986.

Previously, Dr. Carter served on the Board of Xencor, Inc., QLT, Inc., and served as Executive Chairman of
Immune Design Corp. as well as director for over three years. Dr. Carter served as President and Chief
Executive Officer of ZymoGenetics, Inc. and as its Chairman of the Board from 2005 until it was acquired by
Bristol-Myers Squibb in October 2010. Dr. Carter was the Chief Scientific Officer of Novo Nordisk and
previously he held positions in research at Zymogenetics and G.D. Searle & Co. Ltd.

Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in
Microbiology from Queen Elizabeth College, University of London.